



Investing in our future

# The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twentieth Board Meeting  
Addis Ababa, Ethiopia 9 - 11 November 2009

## AMFm Implementation

### Decision Point GF/B20/DP24:

The Board refers to its earlier decisions regarding the Affordable Medicine Facility - malaria ("AMFm") and clarifies its intent that the Global Fund will only expand from Phase 1 (the pilot phase) of AMFm to a global scale-up on the basis of evidence gathered during the pilot phase that the initiative is likely to achieve its four stated objectives: (i) increased ACT affordability, (ii) increased ACT availability, (iii) increased ACT use, including among vulnerable groups, and (iv) "crowding out" oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine by gaining market share. The Board further clarifies that it will consider evidence that the AMFm will achieve these four objectives more cost-effectively than other financing models that aim to achieve similar objectives solely or principally through the expansion of public sector services (i.e., public health facilities and community health workers only).

The Board requests the AMFm Ad Hoc Committee to review the findings of the independent evaluation of AMFm Phase 1 against the four objectives and to make a recommendation to the Board at its first meeting in 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line in countries participating in the pilot. The Board notes that, in addition, it may decide to extend the pilot phase beyond its first meeting in 2012, if necessary. Any such extension would be subject to available funding and the Board reiterates that AMFm Phase 1 is currently funded as a 24-month program and countries should plan accordingly.

The Board decides that, in addition to the AMFm 'identifier', all AMFm co-paid ACTs should bear a logo that is universal for all countries participating in AMFm. During implementation of AMFm Phase 1, based on lessons learned and discussions with participating countries and with due regard to the independent evaluation, other donors should be encouraged and permitted to use the logo on ACTs procured directly by such donors, provided that such ACTs meet the Global Fund's quality assurance policy. The Board requests RBM to work with participating countries, donors and all partners to coordinate the progress towards a universal logo for all quality-assured ACTs.

The Board approves the revised AMFm Phase 1 Policy attached as Annex 1 to the Report of the AMFm Ad Hoc Committee to the Board (GF/B20/7).

This decision does not have material budgetary implications.

*Signed: 11 November 2009*

\_\_\_\_\_  
Eiji Yamamoto  
Rapporteur

\_\_\_\_\_  
Christoph Benn  
Secretariat



Investing in our future

# The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twentieth Board Meeting  
Addis Ababa, Ethiopia 9 - 11 November 2009

---

## Approval of AMFm Phase 1 Applications

### Decision Point GF/B20/DP25:

The Board approves those AMFm Phase 1 applications recommended for approval by the Technical Review Panel (TRP) as 'Category 1' and 'Category 2', as listed in Annex 1 to the Report of the Technical Review Panel and Secretariat on AMFm Applications (GF/B20/10), subject to paragraphs 2-3 below. The Board's approval is for re-programmed and new grant funding (as the case may be) for a full two-year period for each AMFm Phase 1 application and is not subject to prioritization.

The applicants whose applications are recommended for approval as 'Category 2' shall:

- a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than four weeks after receipt of notification in writing by the Secretariat of the Board's funding decision; and
- b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than 31 January 2010.

For those applications recommended for approval as 'Category 2', if the TRP clarification process is not concluded to the satisfaction of the TRP by the deadline stipulated in paragraph b above, the AMFm application in its entirety will be deemed not approved.

The Board declines to approve for funding those applications recommended by the TRP as 'Category 3' as indicated in Annex 1 in GF/B20/10.

This decision does not have material budgetary implications.

*Signed: 11 November 2009*

---

Eiji Yamamoto  
Rapporteur

---

Christoph Benn  
Secretariat